Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

Exploration of Targeted Anti-tumor Therapy(2020)10.37349/etat.2020.00021Source: DataRank Database

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer is a research paper published in Exploration of Targeted Anti-tumor Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

ensembl doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.58)OA: goldTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Michele Cummings ORCID,Abeer M. Shaaban ORCID,Balkees Abderrahman ORCID,Mark A. Hull ORCID,Philipp Y. Maximov

Live enrichment

PubMed:33210098 PMC:PMC7116369 OpenAlex:https://openalex.org/W3093625839

Cancer Research UK

Grant: C13432/A9047

Yorkshire Cancer Research

Grant: L314

University of Texas MD Anderson Cancer Center

Grant: CA016672

NCI NIH HHS

Grant: P30 CA016672

Medical Research Council

Grant: G116/146

Cancer Research UK

Grant: A9047

National Institutes of Health

Robert Bosch Stiftung

FWCI

0.58

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.explorationpub.com/uploads/Article/A100221/100221.pdf

publisherhttps://www.explorationpub.com/uploads/Article/A100221/100221.pdf

publisherhttps://www.explorationpub.com/Journals/etat/Article/100221

journalhttps://doi.org/10.37349/etat.2020.00021

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33210098

Fields of Study

Inflammatory mediators and NSAID effectsEstrogen and related hormone effectsCancer, Lipids, and Metabolism

Keywords

Breast cancerTamoxifenDownregulation and upregulationCancer researchGene silencingCancerEstrogen receptorTransfectionMedicineInternal medicineOncologyCell cultureBiologyGeneImmunohistochemistrySurvival15-hydroxyprostaglandin DehydrogenaseEndocrine Resistance

Sustainable Development Goals

SDG 0: Good health and well-being

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

FAIR Checklist

Authors (12)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)